Depomed Inc., of Newark, Calif., posted total revenues of $40.6 million and $134.2 million for the fourth quarter and full year, respectively. The firm reported fourth quarter product sales of $18.8 million and posted total product sales of $58.3 million for the full year, up 112 percent over 2012. Sales of postherpetic neuralgia drug Gralise (gabapentin) reached $11.7 million for the quarter and $36.2 million for the full year, while sales of pain drug Zipsor (diclofenac potassium) totaled $5.7 million and $20.3 million for the fourth quarter and full year, respectively. Net income for the fourth quarter was $41.8 million, or 72 cents per share. For the full year, net income totaled $43.3 million, or 75 cents per share. As of Dec. 31, the company had a cash position of about $276 million. Shares of Depomed (NASDAQ:DEPO) gained $1.44 to close Thursday at $14.94.

Horizon Pharma Inc., of Deerfield, Ill., reported fourth quarter and full year 2013 net sales totaling $30.1 million and $74 million, respectively. Net sales of Duexis (ibuprofen/famotidine) for the quarter reached $23.1 million, while sales for 2013 were $59 million, a 473 percent increase over 2012 sales. The company’s net loss for the fourth quarter was 4 cents per share vs. analyst estimates of a loss of 8 cents per share. As of Dec. 31, Horizon had about $80.5 million in cash and equivalents. Late last year, Horizon added to its portfolio the gastric-friendly nonsteroidal anti-inflammatory drug Vimovo (naproxen/esomoeprazole magnesium). Shares of Horizon (NASDAQ:HZNP) lost 57 cents Thursday to close at $13.05. (See BioWorld Today, Nov. 20, 2013.)

Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., said fourth quarter global net sales of Relistor (methylnaltrexone bromide) were $19 million, an increase of 296 percent over third quarter sales and 263 percent over the fourth quarter of 2012. Relistor’s 2013 sales were $39.4 million compared to $33.2 million in 2012. Relistor is exclusively licensed to Salix Pharmaceuticals Ltd., of Raleigh, N.C., to treat opioid-induced constipation, which paid Progenics royalty income of approximately $2.9 million for the fourth quarter, compared to $800,000 in the fourth quarter of 2012. Royalty income for the year was $5.9 million compared to $5 million for 2012. Progenics reported a net loss of $8.6 million for the fourth quarter, or 14 cents diluted per share, compared to a net loss of $300,000, or 1 cent diluted per share in the same period a year earlier. Net loss for the year was $42.6 million, compared to $35.4 million in 2012. The company attributed the difference to partnering transactions a year earlier. Progenics reported cash, equivalents and securities of $68.1 million as of Dec. 31, representing a decrease of $9.7 million for the quarter and an increase of $6 million from year-end 2012. Progenics also said it is initiating clinical development of MIP-1095, a PSMA-targeted small-molecule radiopharmaceutical to treat prostate cancer, with Memorial Sloan Kettering Cancer Center designated as the principal site for the phase I study. The trial is expected to begin enrolling patients following the submission of an investigational new drug application later this year.